

## Supplementary Materials

**Table S1.** Examination parameters for intracellular cytokines and plasma cytokine/chemokines.

### 1.1 Flow cytometry analysis

Molecule	Color	Clone	Isotype	Supplier
Lineage markers (Cell-surface staining)				
CD3	PerCP-Cy5.5	17A2	Rat IgG2b, κ	
CD4	PE-Cy7	A161A1	Rat IgG2b, κ	
CD8	APC-Cy7	53-6.7	Rat IgG2a, κ	
CD19	APC-Cy7	6D5	Rat IgG2a, κ	BioLegend
CD56	BV510	HCD56	Mouse IgG1, κ	
CD14	PE-Cy7	63D3	Mouse IgG1, κ	
Activation molecules (Cell-surface staining)				
CD25	FITC	M-A251	Mouse IgG1, κ	
CD69	BV510	FN50	Mouse IgG1, κ	
CD86	PerCP-Cy5.5	BU63	Mouse IgG1, κ	BioLegend
HLA-DR	PE	L243	Mouse IgG2a, κ	
CTLA-4	BV421	BNI3	Mouse IgG2a, κ	
Cytokines (Intracellular staining)				
IL-1β	AF647	JK1B-1	Mouse IgG1, κ	BioLegend
IL-1RA	FITC	CRM17	Mouse IgG1	eBioscience
IL-6	Pacific Blue	MQ2-13A5	Rat IgG1, κ	
IL-10	BV421	JES3-9D7	Rat IgG1, κ	
IL-17	PE	9B10	Rat IgG2a, κ	
IFN-γ	APC	4S.B3	Mouse IgG1, κ	BioLegend
TNF-α	BV510	MAb11	Mouse IgG1, κ	
Granzyme A	FITC	CB9	Mouse IgG1, κ	
FoxP3	AF647	150D	Mouse IgG1, κ	
1.2 Plasma cytokine/chemokine				
Th1-related cytokines	IFN-γ, TNF-α, IFN-γ-inducible protein 10 (IP-10)			
Th2-related cytokines	IL-4, IL-5, Eotaxin			
Th17-related cytokines	IL-6, IL-8, IL-17, granulocyte colony-stimulating factor (G-CSF), and granulocyte macrophage colony-stimulating factor (GM-CSF)			
Treg-related cytokine	IL-10			

---

Others

---

IL-1 $\beta$ , IL-1RA, IL-12, IL-15, basic fibroblast growth factor (FGF-basic), Chemokine ligand (CCL) 2, MCP-1, CCL3 (MIP-1 $\alpha$ ), CCL4 (MIP-1 $\beta$ ), platelet-derived growth factor-bb (PDGF-bb), regulated on activation, normal T expressed and secreted (RANTES), and vascular endothelial growth factor (VEGF)

---

**Table S2.** Comparison of intracellular cytokine levels between patients with West syndrome and the control participants.

		1	2	3	4	5	6	7	8	9	10	11	12	13
Monocytes	IL-1β	4.63	3.92	4.27	2.75	6.44	16.32	59.10	15.64	19.14	6.61	1.83	39.38	6.66
	IL-1RA	1.01	0.28	4.72	2.92	0.49	0.03	48.82	0.52	0.42	0.28	0.34	0.10	7.57
	IL-6	0.34	0.08	0.21	0.33	0.09	0.00	1.03	0.05	0.10	0.19	0.03	0.44	0.00
	TNF-α	1.21	0.78	0.35	0.56	0.08	0.00	2.30	0.47	0.54	0.50	0.27	15.15	0.10
CD4+ T cells	IFN-γ	0.57	1.47	0.96	0.41	0.52	0.00	0.20	0.01	0.02	0.02	0.01	1.58	0.05
	GranzymeA	0.32	1.16	2.67	0.76	0.39	0.00	0.20	0.13	0.35	0.58	0.50	0.72	0.16
	IL-17	0.28	1.11	5.72	0.38	0.61	0.08	0.57	0.06	0.02	0.06	0.17	0.10	0.03
	IL-10	0.13	1.11	11.94	0.27	0.74	0.04	1.69	0.09	0.03	0.05	0.05	0.11	0.10
	IL-1β	0.13	0.21	0.30	0.02	0.47	0.35	0.34	0.34	0.85	0.82	0.17	0.04	0.20
	IL-1RA	0.72	0.33	0.43	0.26	0.10	3.96	6.19	1.02	2.01	1.13	6.20	0.04	1.01
	IL-6	0.26	0.07	0.38	0.25	0.01	0.00	0.08	0.02	0.02	0.01	0.01	0.07	0.00
	TNF-α	0.16	0.42	1.72	0.61	0.09	0.00	0.08	0.02	0.02	0.01	0.01	0.07	0.00
	IFN-γ	20.77	15.33	7.34	5.81	0.21	0.01	1.15	0.12	0.12	0.06	0.00	0.64	0.04
	Granzyme A	0.51	0.40	6.76	1.85	0.65	0.01	16.47	0.19	0.27	0.93	0.29	0.17	0.15
CD8+ T cells	IL-17	0.08	0.36	5.03	0.10	0.18	0.03	0.30	0.01	0.01	0.00	0.07	0.02	0
	IL-10	0.09	0.31	5.46	0.08	0.20	0.01	2.36	0.02	0.02	0.03	0.04	0.04	0.01
	IL-1β	0.15	0.38	1.42	1.92	0.81	0.69	0.34	0.16	0.47	0.16	0.07	0.35	0.03
	IL-1RA	1.56	1.07	0.59	0.41	0.23	0.23	0.10	0.65	1.50	1.34	1.19	0.00	0.19
	IL-6	8.94	6.39	0.24	0.14	0.02	0.00	0.02	0.00	0.02	0.06	0.00	0.00	0.00
NKT-like cells	TNF-α	0.02	0.04	2.66	1.16	0.04	0.00	0.16	0.00	0.07	0.06	0.00	0.03	0.00
	IFN-γ	0.00	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Granzyme A	0.01	0.00	0.03	0.04	0.02	0.00	0.08	0.01	0.03	0.14	0.08	0.00	0.00
NK cells	IFN-γ	9.42	2.50	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00
	Granzyme A	10.17	4.21	0.03	0.04	0.00	0.00	0.04	0.00	0.07	0.69	0.23	0.16	0.00
B cells	IFN-γ	0.01	0.00	0.02	0.04	2.00	0.07	0.04	0.01	0.00	0.01	0.00	0.00	0.24
	Granzyme A	0.82	0.21	0.15	1.89	1.24	0.00	4.54	0.16	0.31	0.46	0.62	0.02	0.15

**Table S3.** Plasma cytokine/chemokine concentrations of patients with West syndrome and control group participants.

	(pg/ml)	West syndrome group	Control group	P-value
<b>Th1</b>	IFN- $\gamma$	11.04 (9.37–76.01)	12.1 (8.1–28.7)	1.00
	TNF- $\alpha$	18.12 (4.26–63.83)	31.27 (8.08–44.94)	0.96
	IP-10	269.64 (157.97–435.02)	2917.3 (295.06–11456.77)	0.10
	IL-2	4.06 (2.69–7.86)	3.52 (0.91–4.13)	0.28
<b>Th 2</b>	IL-4	1.83 (1.48–2.72)	1.27 (0.7–2.18)	0.83
	IL-5	36.0 (18.3–62.0)	19.91 (0.6–40.78)	0.64
	Eotaxin	52.11 (36.38–65.24)	303.18 (64.28–806.55)	0.37
<b>Th 17</b>	IL-6	3.04 (2.58–17.03)	3.96 (3.78–14.08)	0.03
	IL-8	10.73 (7.13–1745.25)	6.79 (5.30–18.31)	0.76
	IL-17	4.51 (3.12–8.97)	6.65 (3.07–10.88)	1.00
	G-CSF	87.06 (70.79–804.06)	70.6 (20.02–103.79)	0.58
	GM-CSF	0.84 (0.32–2.28)	1.41 (0.4–6.055)	0.96
<b>Treg</b>	IL-10	6.12 (4.71–6.40)	7.68 (2.73–10.19)	0.15
<b>Others</b>	IL-1 $\beta$	0.71 (0.53–11.53)	0.75 (0.53–1.11)	0.63
	IL-1RA	409.6 (377.29–1804.2)	293.93 (25.15–1070.17)	0.18
	IL-12	2.48 (1.89–4.56)	2.74 (2.09–4.00)	0.10
	IL-15	254.03 (184.36–291.81)	259.4 (0.00–309.37)	0.72
	FGF basic	30.45 (21.86–63.29)	29.8 (6.67–37.0)	1.00
	CCL2 (MCP-1)	119.64 (84.75–664.79)	49.1 (35.63–81.40)	0.64
	CCL3 (MIP-1 $\alpha$ )	0.85 (0.78–58.9)	0.71 (0.4–0.87)	0.96
	CCL4 (MIP-1 $\beta$ )	146.76 (128.77–845.47)	125.3 (37.4–168.24)	0.70
	PDGF-BB	383.42 (283.77–813.76)	52.988 (222.63–1236.25)	0.64
	RANTES	8436.94 (5442.4–8603.1)	3257.77 (2020.7–8216.72)	0.72
	VEGF	441.64 (387.97–481.94)	438.75 (22.11–503.54)	0.18